Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro.

OBJECTIVE: To investigate the in vitro microbicidal and cytocidal potency of monocaprin dissolved in pharmaceutical hydrogel formulations and to evaluate their potential use as vaginal microbicides against sexually transmitted pathogens such as herpes simplex virus type 2 (HSV-2), human immunodeficiency virus type 1 (HIV-1), Chlamydia trachomatis, and Neisseria gonorrhoeae. METHODS: Gel formulations were mixed with equal volumes of virus/bacteria suspensions in culture medium and incubated for 1 and 5 minutes. The reduction in virus/bacteria titre was used as a measure of microbicidal activity. Similarly, gels were mixed with human semen to study their effect on leucocytes. The toxicity of the gels was tested in rabbits by the standard vaginal irritation test. RESULTS: Gels containing 20 mM of monocaprin caused a greater than 100,000-fold inactivation of HSV-2 and Neisseria in 1 minute and of Chlamydia in 5 minutes. Similarly, the gels caused a greater than 10,000-fold inactivation of HIV-1 in semen in 1 minute. They caused more than a 10,000-fold reduction in the number of viable leucocytes in semen in 1 minute. No toxic effect on the vaginal mucosa of rabbits was observed after daily exposure for 10 days. CONCLUSIONS: Hydrogels containing monocaprin are potent inactivators of sexually transmitted viruses and bacteria in vitro. This simple lipid seems to be a feasible choice as a mucosal microbicide for prevention of sexually transmitted infections. It is a natural compound found in certain foodstuffs such as milk and is therefore unlikely to cause harmful side effects in the concentrations used.

[1]  H. Thormar,et al.  In Vitro Inactivation of Chlamydia trachomatis by Fatty Acids and Monoglycerides , 1998, Antimicrobial Agents and Chemotherapy.

[2]  W. Stamm,et al.  Susceptibility of Chlamydia trachomatisto Chlorhexidine Gluconate Gel , 1998, Antimicrobial Agents and Chemotherapy.

[3]  M. De Brabander,et al.  Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients , 1996, AIDS.

[4]  J. Ito,et al.  Reducing the risk of Chlamydia trachomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Thormar,et al.  Antimicrobial activity of lipids added to human milk, infant formula, and bovine milk. , 1995, The Journal of nutritional biochemistry.

[6]  E. Wallach,et al.  The biologic significance of white blood cells in semen. , 1995, Fertility and sterility.

[7]  P. Feldblum,et al.  Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. , 1995, Genitourinary medicine.

[8]  Regina M. Oliver,et al.  Barrier contraceptive use and HIV infection among high‐risk women in Cameroon , 1993, AIDS.

[9]  J. Fortney,et al.  A Dosing Study of Nonoxynol-9 and Genital Irritation , 1993, International journal of STD & AIDS.

[10]  D. Phillips,et al.  Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. , 1993, Biology of reproduction.

[11]  K. Holmes,et al.  Virucides in Prevention of HIV Infection Research Priorities , 1993, Sexually transmitted diseases.

[12]  T. Fleming,et al.  Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. , 1992, JAMA.

[13]  A. Gettie,et al.  The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. , 1992, Fertility and sterility.

[14]  S. Niruthisard,et al.  The Effects of Frequent Nonoxynol‐9 Use on the Vaginal and Cervical Mucosa , 1991, Sexually transmitted diseases.

[15]  V L Murphy,et al.  Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. , 1991, The Journal of infectious diseases.

[16]  A. Dalgleish,et al.  INACTIVATION OF HIV BY NONOXYNOL-9 , 1988, The Lancet.

[17]  H. Thormar,et al.  Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides , 1987, Antimicrobial Agents and Chemotherapy.

[18]  W. Mccormack,et al.  Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro , 1985, Antimicrobial Agents and Chemotherapy.

[19]  M. Arsenakis,et al.  Effect of antiviral lipids, heat, and freezing on the activity of viruses in human milk. , 1979, The Journal of infectious diseases.

[20]  M. Weis,et al.  Inactivation of Herpes Simplex Viruses by Nonionic Surfactants , 1978, Antimicrobial Agents and Chemotherapy.

[21]  B. Singh,et al.  Virucidal effect of certain chemical contraceptives on Type 2 herpesvirus. , 1976, American journal of obstetrics and gynecology.

[22]  B. Singh,et al.  The effect of vaginal lubricants on Neisseria gonorrhoeae. , 1976, American journal of obstetrics and gynecology.

[23]  A. Conley,et al.  Fatty Acids and Derivatives as Antimicrobial Agents , 1972, Antimicrobial Agents and Chemotherapy.

[24]  H. Utidjian,et al.  Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of vaginal contraceptive and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoeae. , 1972, The British journal of venereal diseases.

[25]  A. Klainer Manual of Clinical Microbiology , 1970 .

[26]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[27]  Recommendations for the development of vaginal microbicides. International Working Group on Vaginal Microbicides. , 1996, AIDS.

[28]  Y. Ohtsuki,et al.  Type C Virus-Producing Cell Lines Derived from Adult T Cell Leukemia , 1982 .

[29]  T. A. Hagan,et al.  Detection , Isolation , and Continuous Production of Cytopathic Retroviruses ( HTLV-III ) from Patients with AIDS and Pre-AIDS , 2022 .